Call for papers: Advances in Cancer Immunotherapy
We are pleased to announce that Journal of Experimental & Clinical Cancer Research has launched a new thematic series on “Advances in Cancer Immunotherapy” to help summarize recent highlights in this field. Click here for further details on the series and for submission information.
Submission deadline: 31st May 2019
Click here to access all thematic series published to date in the Journal of Experimental & Clinical Cancer Research.
Featured article: Activities of stromal and immune cells in HPV-related cancers
The mechanism for innate immune response is essential for preventing cancer development. Human papillomavirus (HPV) may cause the evasion of those mechanisms, which leads to carcinogenic host cell transformation. Therefore, immunotherapies often aim to strengthen the host's immune cells, but more recent studies have considered the importance of stromal cells (i.e. fibroblasts) in HPV-related carcinogenesis. In this review, Marconi Rego Barros Jr. et al. discuss stromal and immune cell mechanisms modulated by HPV and outline existing and potential immunotherapies targeting such mechanisms in HPV-related cancers.
Click here to access the full article.
Click here to access all of the reviews published to date in Journal of Experimental & Clinical Cancer Research.
Aims and scope
Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.
Please click here to read more.
Editor-in-Chief
Mauro Castelli, Regina Elena National Cancer Institute, Italy
If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to:
Celebrating the 10th anniversary partnership with BMC
2018 marks the 10th anniversary of the partnership between the Journal of Experimental & Clinical Cancer Research and BMC.
Over the past decade, the journal has established itself among some of the top Oncology titles in Journal Citation Reports. Click here to look back at some of the journal’s milestone achievements and best content from the past 10 years.
2017 Impact Factor
We are delighted to share with our readers that Journal of Experimental & Clinical Cancer Research has an Impact Factor of 6.217 and is currently ranked at 33 out of 222 (Q1) in the Oncology category of Journal Citation Reports (Clarivate Analytics, 2018).
We would like to extend our appreciation to all Editorial Board Members, authors and peer reviewers who have contributed to the journal and enabled this achievement.
Archival content
Journal of Experimental & Clinical Cancer Research has been publishing since 1982. Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print. For enquiries about previous content, please contact us on:
Reviewer Acknowledgement and New Recruitment
The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to jeccreditorial@gmail.com
Advertisement
-
-
Owned by the Association for International Promotion & Study in Tumors (APSIT)
-
Official journal of the Regina Elena National Cancer Institute, Scientific Director Gennaro Ciliberto, Rome, Italy
-
- Editorial Board
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
Speed
27 days to first decision for reviewed manuscripts only
33 days to first decision for all manuscripts
97 days from submission to acceptance
21 days from acceptance to publication
Citation Impact
6.217 - 2-year Impact Factor
5.280 - 5-year Impact Factor
1.350 - Source Normalized Impact per Paper (SNIP)
2.000 - SCImago Journal Rank (SJR)
Usage
724,993 Downloads
392 Altmetric Mentions
Advertisement
